{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.52","upperLimit":"10.84","value":"5.59"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"Time to MMR is the time from first study drug intake to first major molecular response computed only for participants who achieved MMR.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients newly diagnosed in Chronic phase. Diagnosis within 6 months of date of first cytogenetic analysis confirming Philadelphia chromosome with (9;22) translocation by standard conventional cytogenetic analysis.","id":"OG000","title":"Newly Diagnosed and Untreated Ph+ CML in First CP"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set (FAS): All patients who received at least one dose of study medication.","reportingStatus":"POSTED","timeFrame":"From first dosing to the first MMR within 66 cycles period","title":"Time to First MMR Among Newly Diagnosed Ph+ CML-CP Patients Who Achieved MMR","type":"SECONDARY","unitOfMeasure":"Months"}